Related Experiment Video
Updated: Aug 8, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Low and intermediate risk prostate cancer-- role of hormonal therapy with external beam radiation therapy
Jarad Martin1, Robert Bristow, Padraig Warde
1Department of Radiation Oncology, University of Toronto and Radiation Medicine Program, Princess Margaret Hospital, Toronto, Ontario, Canada.
Abstract:
Risk categorization based on pre-treatment PSA, clinical stage and Gleason score is now widely used in the management of patients with localized prostate cancer. In patients with low-risk disease (cT1-T2a, PSA < 10 ng/ml and Gleason score < 6) there is no role for the routine use of adjunctive hormonal therapy. In intermediate-risk patients (T1-T2, PSA < 20 ng/ml and Gleason
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
